Are we getting a lower low after a lower high? It certainly can be the case but there is enough congestion at these levels and volume is low enough into the end of the year that I can see this not sticking as a breakdown. Of course, we really do need to break above the […]
December 18th Biotech Update
I know sentiment is not great in the sector but honestly if you take a step back we still remain rangebound. I know there are red hot sectors in the market, but it seems increasingly narrow set of stocks that are the beneficiaries. You just need to compare the NASDAQ with the DOW to see […]
December 12th Biotech Update
Let me know if you heard this before? We seem to be in a range bound market with the sector and appear to be lagging the broader markets. We are still waiting for a big pick up in news and, in particular, M&A. It seems that most people are using the sector more as a […]
December 9th Biotech Update
A pretty neutral start to the week but we also do not have a ton of sector moving news. I do not think we are quite at the point where trading slows down for the year but we are getting there. I would not be surprised to see continued rangebound trading heading into the end […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
